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Nifedipine was reported to enhance urinary iron excretion in iron overloaded mice.
However, it remains unknown how nifedipine stimulates urinary iron excretion in the
kidney. We speculated that nifedipine might inhibit the TfR1/ DMT1 (transferrin receptor
1/divalent metal transporter1)-mediated iron uptake by proximal tubule cells in addition
to blocking L-type Ca2+ channels, leading to an increase in iron in lumen-fluid and
then urinary iron excretion. To test this hypothesis, we investigated the effects of
nifedipine on iron content and expression of TfR1, DMT1 and ferroportin1 (Fpn1) in
WKPT-0293 Cl.2 cells of the S1 segment of the proximal tubule in rats, using a graphite
furnace atomic absorption spectrophotometer and Western blot analysis, respectively.
We demonstrated for the first time that nifedipine significantly enhanced iron content
as well as TfR1 and DMT1 expression and had no effect on Fpn1 levels in the cells.
We also found that ferric ammonium citrate decreased TfR1 levels, increased Fpn1
expression and had no effect on DMT1 content, while co-treatment with nifedipine and
FAC increase TfR1 and DMT1 expression and also had no effect on Fpn1 levels. These
findings suggest that the nifedipine-induced increase in cell iron may mainly be due to
the corresponding increase in TfR1 and DMT1 expression and also imply that the effects
of nifedipine on iron transport in proximal tubule cells can not explain the increase in
urinary iron excretion.
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INTRODUCTION
Plasma iron is tightly bound to Tf, a 78-kDa circulating protein that is assumed to not cross
the glomerulus filter, because of its low protein permeability (Aisen, 1994; Linder, 2013). The
kidney has therefore been regarded as more or less irrelevant in terms of iron handling,
and for a long time, iron metabolism in the kidney also received relatively little attention
(Smith and Thévenod, 2009; Thévenod and Wolff, 2016). However, a number of recent
studies have provided evidence for the presence of many, if not all of the iron transporters
and receptors in renal tubular cells, including TfR1 (Zhang et al., 2007; Moulouel et al.,
2013), cubilin (a novel Tf receptor) (Kozyraki et al., 2001), divalent metal transporter 1
(DMT1) (Canonne-Hergaux and Gros, 2002) at the apical membrane, and ferroportin 1 (Fpn1)
Abbreviations: BSA, bovine serum albumin; DMT1, divalent metal transporter1; DMT1+ IRE, divalent metal transporter1
with iron response element; DMT1− IRE, divalent metal transporter1 without iron response element; FAC, ferric ammonium
citrate; Fpn1, ferroportin1; Tf, transferrin; TfR1, transferrin receptor 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide.
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(Wolff et al., 2011) at the basolateral membrane. Previous studies
also have suggested that Tf might be able to filter from the
glomerulus (Alfrey and Hammond, 1990; Norden et al., 2001;
Kozyraki et al., 2001), and that transferrin-bound iron (Tf-fe)
could be reabsorbed by proximal tubule cells via TfR1- or cubilin-
mediated endocytosis (Kozyraki et al., 2001; Moulouel et al.,
2013). Measurement of iron re-absorption in the rat kidney
in vivo has shown that, under physiological conditions, about
0.4 mg iron is filtered daily and about 0.7% is excreted in the urine
(Wareing et al., 2000). These novel data imply that the kidney
plays a previously unsuspected role in systemic iron balance, and
contributes to general iron homeostasis (Martines et al., 2013;
Veuthey et al., 2014).
A recent study reported that L-type Ca2+ channel blockers of
the dihydropyridine type, including nifedipine and niguldipine,
markedly stimulated iron transport in both COS-7 and HEK293T
cells, which were transiently transfected with DMT-1A with
IRE, and enhanced liver iron mobilization as well as urinary
iron excretion in animal models of iron overload (Ludwiczek
et al., 2007). These results revealed a new pharmacological
property of nifedipine and related compounds for the treatment
of iron overloaded disorders by increasing excretion of iron from
the kidney. However, it is unknown how nifedipine stimulates
urinary iron excretion in the kidney. In the rat heart, nifedipine
was demonstrated to be able to inhibit L-type Ca2+ channel-
mediated non-transferrin-bound iron (NTBI) uptake by isolated
hearts and ventricular myocytes (Tsushima et al., 1999). The
presence of DMT1 has been well-documented in the heart (Ke
et al., 2003; Zhao et al., 2010). It has also been shown that
DMT1 is a voltage-dependent divalent-cation transporter and
NTBI uptake-mediated by DMT1 has similar voltage dependency
to that of the L-type Ca2+ channel (Tsushima et al., 1999).
Although it is currently undetermined whether L-type Ca2+
channel blockers affect DMT1 transport properties, it is possible
that the nifedipine-induced reduction in iron uptake, as observed
in isolated rat hearts and ventricular myocytes, is mediated by the
inhibition of not only the L-type Ca2+ channel, but also DMT1.
Based on these novel findings, we therefore speculated that
nifedipine might be able to inhibit TfR1/DMT1-mediated iron
uptake in addition to blocking the L-type Ca2+ channels and
their associated iron uptake, and then reduce the amount of iron
transport across the cell membrane from tubular lumen-fluid to
the inside of cells in the proximal tubule (an important segment
of physiological re-absorption), leading to an increase in iron
in the final urine. To test this hypothesis, in the present study
we investigated the effects of nifedipine on iron content, as well
as the expression of iron uptake proteins TfR1 and DMT1 and
iron release protein Fpn1 in WKPT-0293 Cl.2 cells of the S1
segment of the proximal tubule of normotensive Wistar-Kyoto
rats (RPTC).
MATERIALS AND METHODS
Materials
Unless otherwise stated, all chemicals, including MTT and
mouse monoclonal anti-β-actin, were obtained from the Sigma
Chemical Company, St. Louis, MO, USA. The mouse anti-rat
TfR1 antibody was purchased from Invitrogen, Carlsbad, CA,
USA, and the rabbit polyclonal anti-mouse Fpn1 antibody from
Chemicon International, Temecula, CA, USA. The rabbit anti-
rat DMT1 + IRE and DMT1 − IRE polyclonal antibodies were
bought from the Alpha Diagnostic International Company, San
Antonio, TX, USA, and goat anti-rabbit or anti-mouse IRDye
800 CW secondary antibodies from LI-COR Biosciences, Lincoln,
NE, USA. Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s
F-12 was obtained from GIBCO, Grand Island, NY, USA and BSA
from the Calbiochem-Novabiochem Corporation, San Diego,
CA, USA. The scintillation cocktail and tubes were obtained
from the Beckman Coulter Company, Fullerton, CA, USA. All
experimental protocols were performed according to the Animal
Management Rules of the Ministry of Health of China, and
approved by the Animal Ethics Committees of Fudan University
and The Chinese University of Hong Kong.
Cell Culture
Immortalized cells (WKPT-0293 Cl.2) from the S1 segment of the
proximal tubule of normotensive Wistar-Kyoto rats (RPTC) were
cultured as previously described Woost et al. (1996). Briefly, cells
were maintained in renal tubular epithelium medium composed
of DMEM and F-12 [nutrient mixture F-12 (Ham)] at a ratio
of 1:1, supplemented with 15 mM HEPES, 1.2 mg/ml NaHCO3,
5 µg/ml Tf, 10 ng/ml epidermal growth factor, 100 U/ml
penicillin G, 100 mg/ml streptomycin sulfate, and 10% fetal calf
serum. Cells were plated at a density of 5 × 104/ml on collagen-
coated flasks, passaged at 80% confluency, and split 1:10, twice a
week.
Assessment of Cell Viability
Cell viability was assessed using an MTT assay as previously
described (He et al., 2008; Du et al., 2009). Briefly, a total of 25 µl
MTT (1 g/L in PBS) was added to each well before incubation was
conducted at 37◦C for 4 h. The assay was stopped by the addition
of a 100 µl lysis buffer (20% SDS in 50% N’Ndimethylformamide,
pH 4.7). Optical density (OD) was measured at the 570 nm
wavelength by the use of an ELX-800 microplate assay reader
(Bio-tek, Winooski, VT, USA) and the results were expressed as a
percentage of the absorbance measured in the control cells.
Graphite Furnace Atomic Absorption
Spectrophotometer
Total iron in the WKPT-0293 Cl.2 cells was determined using a
graphite furnace atomic absorption spectrophotometer (GFAAS,
Perkin Elmer, Analyst 100) as previously described (Chang
et al., 2005; Ke et al., 2005). The cells were diluted 1:20
(wt/v) with HEPES buffer and homogenized with a sonicator
(MSE Soniprep 150 Ultrasonic Disintegrator, MSE Scientific
Instruments, England). A 50-µl portion of the homogenate was
added to an equal volume of ultra-pure nitric acid in a 0.5 ml
polypropylene microfuge tube, digested for 48 h at 50◦C, and
diluted 1:40 with 3.12 mmol/L nitric acid for iron analysis.
Standard curves (0–40 ppb) were prepared by diluting iron
standard with blanks prepared from homogenization reagents
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FIGURE 1 | Effect of nifedipine and FAC treatment on the viability of
WKPT-0293 Cl.2 cells. WKPT-0293 Cl.2 cells were treated with FAC
(100 µM) or nifedipine (1, 10, 100 µM) alone for 16 h (A); or FAC (100 µM)
with nifedipine (1, 10, 100 µM) for 16 h (B), cell viability was then evaluated
using the MTT assay as described in the Section “Materials and Methods.”
Data were presented as means ± SEM (n = 8). ∗p < 0.05 versus the control.
in 0.2% HNO3. Standards and digested samples were read in
triplicate by injecting 50 µl aliquots including 0.05 mg Mg(NO3)2
as matrix modification into graphite furnace. Absorbance
readings at 248.3 nm, slit at 0.2 nm, pretreatment temperature
at 1400◦C, atomization temperature at 2400◦C were recorded.
Western Blot Analysis
WKPT-0293 Cl.2 cells that received different treatments were
washed with ice-cold PBS, homogenized with lysis buffer and
then subjected to sonication using a Soniprep 150 (MSE Scientific
Instruments, London, UK). After centrifugation at 10,000 g for
15 min at 4◦C, the supernatant was collected and protein content
was determined using the Bradford assay kit (Bio-Rad). Aliquots
of the cell extract containing 50 µg of protein were diluted in 2 µl
FIGURE 2 | Nifedipine treatment increased iron level in WKPT-0293
Cl.2 cells. WKPT-0293 Cl.2 cells were treated with FAC (100 µM) (A) or
nifedipine (1, 10, 100 µM) with FAC (100 µM) (B) for 16 h, iron content was
then measured using a GFAAS (graphite furnace atomic absorption
spectrophotometer) as described in the Section “Materials and Methods.” The
data were presented as Mean ± SEM (n = 8). ∗p < 0.05, versus the control
(A) or FAC (B).
of sample buffer (50 mM Tris, pH 6.8, 2% SDS, 10% glycerol,
0.1% bromphenol blue, and 5% β-mercaptoethanol) and heated
for 5 min at 95◦C before SDS-PAGE on 10% gel and transfer to a
pure nitrocellulose membrane. After the transfer, the membrane
was blocked with 5% blocking reagent in Tris-buffered saline
containing 0.1% Tween-20, overnight at 4◦C. The membrane was
then rinsed in three changes of Tris-buffered saline/Tween-20,
incubated in fresh washing buffer once for 15 min and twice
for 5 min, and then incubated overnight at 4◦C with primary
antibodies: rabbit anti-rat DMT1 + IRE, DMT1-IRE polyclonal
antibodies, rabbit anti-mouse Fpn1 polyclonal antibody (1:5000),
and mouse anti-rat TfR1 monoclonal antibody (1:1000). After
three washes, the blots were incubated with goat anti-rabbit
or anti-mouse IRDye 800 CW secondary antibody (1:5000, Li-
Cor) for 1 h at room temperature. The intensity of the specific
bands was detected and analyzed by the Odyssey infrared imaging
system (Li-Cor) (Du et al., 2014; Qian et al., 2014). To ensure
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FIGURE 3 | Nifedipine treatment increased expression of TfR1, DMT1 + IRE and DMT1 − IRE in WKPT-0293 Cl.2 cells. WKPT-0293 Cl.2 cells were
treated with nifedipine (1, 10, 100 µM) for 16 h, and the expression of TfR1 (A), DMT1 + IRE (B), DMT1 + IRE (C), and Fpn1 (D) was then measured by Western
blot analysis. The data were presented as Mean ± SEM (n = 6, % Control). ∗p < 0.05 versus the control.
even loading of the samples, the same membrane was probed with
mouse monoclonal anti-β-actin antibody at a 1:2000 dilution.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism. Data
were presented as mean ± SEM. The differences between the
means were all determined by two-way analysis of variance
(ANOVA). A probability value of P < 0.05 was taken to be
statistically significant.
RESULTS
Effects of Nifedipine and Ferric
Ammonium Citrate (FAC) Treatment on
the Viability of WKPT-0293 Cl.2 Cells
We first investigated the effects of FAC and nifedipine on the
viability of WKPT-0293 Cl.2 by treating the cells with FAC
(100 µM) (Chen et al., 2005) or various concentrations (1, 10,
100 µM) of nifedipine alone for 16 h, and then evaluated cell
viability using an MTT assay. The results showed that there were
no significant differences in viability between the control cells
and the cells treated with 100 µM of FAC or 1 and 10 µM of
nifedipine. However, viability in the cells treated with 100 µM
of nifedipine was found to be significantly lower than that of the
control cells (Figure 1A).
To find out the effects of co-treatment with FAC and
nifedipine on the viability of WKPT-0293 Cl.2 cells, the cells were
treated with FAC (100 µM) plus 1, 10 or 100 µM of nifedipine
for 16 h. The MTT assay demonstrated that viability in the
cells treated with 1 µM of nifedipine plus FAC or FAC alone
were not significantly different from that of the control cells, but
treatment with 10 or 100 µM of nifedipine plus FAC did induce
a significant reduction in cell viability (Figure 1B). The findings
here demonstrated that nifedipine could promote the toxic effects
of FAC on the viability of WKPT-0293 Cl.2 cells.
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FIGURE 4 | Ferric ammonium citrate treatment decreased TfR1 and increased Fpn1 expression in WKPT-0293 Cl.2 cells. WKPT-0293 Cl.2 cells were
treated with FAC (100 µM) for 16 h, and the expression of TfR1 (A), DMT1 + IRE (B), DMT1 − IRE (C), and Fpn1 (D) was then measured by Western blot analysis.
The data were presented as Mean ± SEM (n = 6, % Control). ∗p < 0.05 versus the control.
Nifedipine Treatment Increased Iron
Level in WKPT-0293 Cl.2 Cells
We then examined the effects of nifedipine on iron uptake
in WKPT-0293 Cl.2 cells. The cells were treated with FAC
(100 µM) with different concentrations (0, 1, 10, 100 µM) of
nifedipine for 16 h, and iron content was then measured using
a GFAAS. It was found that treatment with 100 µM of FAC
alone induced a significant increase in iron content, 38.629 fold
of that of the control cells (Figure 2A). The addition of nifedipine
led to a further increase in cell iron levels. Iron contents in
the cells treated with 1, 10, or 100 µM of nifedipine plus
100 µM of FAC were significantly higher than those in the cells
treated with 100 µM of FAC alone. There were no significant
differences between the cells treated with different concentrations
of nifedipine plus FAC (Figure 2B). These results showed that
nifedipine has a role in increasing the iron uptake of WKPT-0293
Cl.2 cells.
Nifedipine Treatment Increased
Expression of TfR1, DMT1 + IRE and
DMT1 − IRE in WKPT-0293 Cl.2 Cells
To find out the potential mechanisms involved in the positive
role of nifedipine on iron uptake by WKPT-0293 Cl.2 cells,
we investigated the effects of nifedipine on the expression
of major iron uptake proteins TfR1, DMT1 + IRE and
DMT1− IRE, as well as iron release protein Fpn1 in the cells. We
demonstrated that nifedipine induced a progressive increase in
TfR1 (Figure 3A) and DMT1 + IRE (Figure 3B) expression but
not in DMT1 − IRE and Fpn1 with the concentrations added.
Although the expression of DMT1 − IRE in cells treated with
1, 10, or 100 µM of nifedipine was significantly higher than
that of the control cells, there were no significant differences
between cells treated with different concentrations of nifedipine
(Figure 3C). Treatment with 1 or 10 µM of nifedipine did
not induce any significant changes in Fpn1 expression, with no
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FIGURE 5 | Co-treatment with nifedipine and FAC increased TfR1, DMT1 + IRE and DMT1 − IRE expression in WKPT-0293 Cl.2 cells. WKPT-0293 Cl.2
cells were treated with 100 µM of nifedipine plus100 µM of FAC for 16 h, and the expression of TfR1 (A), DMT1 + IRE (B), DMT1 − IRE (C), and Fpn1 (D) was then
measured by Western blot analysis. The data were presented as Mean ± SEM (n = 4, % Control). ∗p < 0.05 versus the control.
significant differences being found in Fpn1 content between the
cells treated with 1 or 10 µM of nifedipine and the controls
(Figure 3D). However, treatment with 100 µM of nifedipine was
found to induce a significant reduction in Fpn1 expression in
the WKPT-0293 Cl.2 cells. The data imply that nifedipine likely
increases iron uptake in WKPT-0293 Cl.2 cells via its role in
up-regulating expression of iron uptake proteins.
FAC Treatment Decreased TfR1 and
Increased Fpn1 Expression in
WKPT-0293 Cl.2 Cells
We also investigated the effects of iron-overload on the
expression of TfR1, DMT1 + IRE, DMT1 − IRE and Fpn1 by
treating WKPT-0293 Cl.2 cells with 100 µM of FAC for 16 h.
Western blot analysis showed that FAC treatment induced a
significant reduction in TfR1 (Figure 4A) and an increase in
Fpn1 (Figure 4D) expression, and had no effect on DMT1+ IRE
(Figure 4B) and DMT1− IRE (Figure 4C) expression in WKPT-
0293 Cl.2 cells.
Co-treatment With Nifedipine and FAC
Increased TfR1, DMT1 + IRE and
DMT1 − IRE Expression in WKPT-0293
Cl.2 Cells
Finally, we investigated the effects of co-treatment with
Nifedipine and FAC on the expression of TfR1, DMT1 + IRE,
DMT1 − IRE and Fpn1 by treating WKPT-0293 Cl.2 cells with
100 µM of nifedipine plus100 µM of FAC for 16 h. Western blot
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FIGURE 6 | Hypothetical scheme for the possible effects of nifedipine
on TfR1, DMT1 and Fpn1 expression and iron re-absorption in
proximal tubule cells of kidney.
analysis demonstrated that co-treatment with nifedipine and FAC
led to a significant increase in TfR1 (Figure 5A), DMT1 + IRE
(Figure 5B) and DMT1-IRE (Figure 5C) expression and had no
effect on Fpn1 expression (Figure 5D) in WKPT-0293 Cl.2 cells.
DISCUSSION
The major objective of this study was to find out whether
treatment with the L-type Ca2+ channel blocker nifedipine
could reduce iron uptake by the proximal tubule cells of the
nephron, leading to an increase in the iron content within
luminal fluid and, subsequently to also an increase in urinary
iron excretion in the kidney. We therefore first investigated
the effect of nifedipine on iron content in proximal tubule
cells treated with FAC. We demonstrated for the first time
that nifedipine treatment has a significant role in enhancing,
rather than reducing iron content in WKPT-0293 Cl.2 cells
of the S1 segment of the proximal tubule of normotensive
Wistar-Kyoto rats (RPTC). This unexpected finding, that is,
that nifedipine induces an increase in cell iron content, should
predictably lead to a decrease rather than an increase in
urinary iron excretion. It implies that the effects of nifedipine
on iron transport in proximal tubule cells are not associated
with its induced increase in urinary iron excretion in the
kidney.
To find out the mechanisms involved in the nifedipine-
induced increase in cell iron content, we further examined the
effects of nifedipine and/or FAC on the expression of iron
transport proteins TfR1, DMT1 + IRE, DMT1 − IRE, and
Fpn1 respectively in WKPT-0293 Cl.2 cells. It was found that
FAC alone decreased TfR1 expression, increased Fpn1 expression
and had no effects on DMT1 + IRE and DMT1 − IRE,
nifedipine alone increased TfR1, DMT1+ IRE and DMT1− IRE
expression, and had no effect on Fpn1, while co-treatment
with nifedipine and FAC led to a significant increase in TfR1,
DMT1 + IRE and DMT1 − IRE expression and also had
no effect on Fpn1 expression in WKPT-0293 Cl.2 cells. These
results implied that that the nifedipine-induced increase in
iron content in the cells may mainly be due to the increased
expression of TfR1 and DMT1 (Figure 6). FAC may be either
donor of iron to trarnsferrin in the medium or as an NTBI
source. Most of the iron taken up by the cells was probably
in the form of Tf-Fe via a TfR1 (cell membrane)/ DMT1
(endosomal membrane) pathway because we did not deplete
the intracellular store of Tf by suspending the cells in DMEM–
HEPES medium for a given period (Chang et al., 2007; Qian
et al., 2011) in this study. It is also conceivable, but remains to
be tested, that small amount of the iron may be taken up by
the cells in the form of NTBI via a DMT1-mediated pathway.
In addition, further investigations on how nifedipine enhances
TfR1 and DMT1 expression in this type of cells are needed.
The relevant mechanisms, especially the effects of nifedipine on
the expression of iron regulatory proteins (IRPs) and membrane
potential polarization (Du et al., 2016) need to be clarified as
well.
Studies in Belgarde rats have shown that DMT1, also known as
DCT1 (Gunshin et al., 1997) or NRAMP2 (Fleming et al., 1997),
plays a fundamental role in body iron homeostasis (Fleming
et al., 1998, 1999; Garrick et al., 1999; Gruenheid et al., 1999).
DMT1 is highly expressed in the kidney (Canonne-Hergaux and
Gros, 2002) and is also suggested to play a role in urinary iron
handling (Martines et al., 2013; Veuthey et al., 2014). Therefore,
modulation of renal DMT1 expression may influence renal iron
excretion rate. A recent in vivo study showed that altered dietary
iron intake is a strong modulator of renal DMT1 expression
in male Wistar rats (Wareing et al., 2003). Increasing dietary
iron (an iron-enriched diet, 5 g/kg) was found to decrease
DMT1 expression and increase urinary iron excretion rate,
while decreasing dietary iron (an iron-restricted diet, 50 mg/kg)
caused an increase in DMT1 expression and a decrease in
urinary iron excretion (Wareing et al., 2003). This finding is
different from what was found in the present study, where
we found FAC to have no effect on DMT1. The cause of this
conflict in results is unknown, although it may be partly due
to the differences between experimental conditions in vivo and
in vitro.
DMT1 is found not only in proximal tubule cells, but also in
late thick ascending limbs, early distal tubules, and intercalated
cells of the cortical collecting duct (Ferguson et al., 2001;
Abouhamed et al., 2006). The types of epithelial cells found
at different segments of nephron are different, which is why
different segments have different functions in re-absorption and
secretion for practical ions such as Na+ and K+ (Silverthorn,
2001). Currently it is unknown whether iron handling differs
between different segments of the nephron. It is also unknown
whether the responses of DMT1 to iron differ between different
parts of nephron, although it is certainly possible. In addition,
it has yet to be determined whether iron within the peritubular
capillaries can be moved into the interstitial space, then to tubular
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cells and finally, be deposited into tubular fluid, especially when
there is an increase in serum iron. Furthermore, the role of L-type
Ca2+ channels in iron transport in different segments of the
nephron still need to be clarified. Only after we have the answers
to the above questions, can we fully account for how nifedipine
stimulates urinary iron excretion in the kidney.
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